Anika Therapeutics (ANIK)
NASDAQ:ANIK
Want to see ANIK full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.08Last Year’s EPS
-0.13Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights meaningful commercial momentum (13% revenue growth), strong operational improvements (gross margin up ~8 percentage points and adjusted EBITDA lift), accelerating adoption of Integrity and international product strength, supported by a clean balance sheet and active share repurchase. Key near-term concerns include higher operating expenses (notably a onetime $4.9M severance), regulatory timelines for Hyalofast and CINGAL that remain uncertain, OEM channel timing and mix variability, and caution that Q1 margin levels may not be fully sustained quarter-to-quarter. Overall, the positives around revenue growth, margin improvement, pipeline progress and liquidity outweigh the manageable near-term risks and uncertainties.Company Guidance
Total Revenue Growth
Total revenue of $29.6 million in Q1 2026, up 13% year-over-year, demonstrating top-line momentum.
Commercial Channel Momentum
Commercial channel revenue reached $12.6 million, up 12% year-over-year, driven by regenerative solutions and international OA pain management.
Integrity Adoption and Procedure Growth
Integrity U.S. procedures increased 35% year-over-year, generating nearly $2 million in revenue; Integrity has surpassed 3,000 cases with new surgeon users per month growing at a double-digit rate month-over-month and demand for larger sizes tracking ahead of expectations.
International OA Pain Management Strength
International OA pain management revenue was $8.9 million (nearly $9M), up 9% year-over-year, with market share gains for MONOVISC and CINGAL across multiple regions.
OEM Channel Revenue Increase
OEM channel revenue of $17.0 million, up 14% year-over-year, primarily driven by favorable order timing for U.S. OA pain management products and non-orthopedic OEM products.
Gross Margin Expansion
GAAP gross margin improved to 64% from 56% in the prior year (an increase of ~8 percentage points), reflecting higher productivity, increased throughput and lean manufacturing benefits.
Adjusted EBITDA Improvement
Total adjusted EBITDA was $4.3 million for the quarter, driven by gross margin expansion and operating leverage; management noted adjusted EBITDA increased by more than $4 million versus the prior year quarter.
Strong Balance Sheet and Liquidity
Ended the quarter with $41 million in cash and no debt, providing flexibility to invest in operations and the commercial channel.
Capital Return Activity
Completed a $15 million 10b5-1 repurchase program and, as part of a second 10b5-1 plan, purchased $15 million of stock at an average price of $10.76, reflecting active capital allocation.
Regulatory and Product Progress (EU and Pipeline)
CINGAL achieved European Union MDR certification with expanded indications (knee, hip, shoulder, ankle); Hyalofast PMA review is ongoing; CINGAL bioequivalence enrollment remains on track; early-stage HYAFF-based suture and tape preclinical data are encouraging.
Operational Improvements and Cost Discipline
Notable manufacturing productivity and throughput gains, reduced nonstandard work, equipment investments and lean initiatives are underway; management highlighted deliberate operational transformation and disciplined SG&A control (excluding onetime severance).
ANIK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ANIK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | $15.26 | $12.39 | -18.81% |
Feb 26, 2026 | $10.94 | $12.79 | +16.91% |
Nov 05, 2025 | $9.63 | $9.85 | +2.28% |
Jul 30, 2025 | $11.16 | $8.10 | -27.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Anika Therapeutics (ANIK) report earnings?
Anika Therapeutics (ANIK) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Anika Therapeutics (ANIK) earnings time?
Anika Therapeutics (ANIK) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ANIK EPS forecast?
ANIK EPS forecast for the fiscal quarter 2026 (Q2) is -0.08.